Avivagen Inc.

04/20/2023

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, today announced the results of its annual general meeting of shareholders held on April 19, 2023.

Ottawa, ON /Business Wire/ April 19, 2023 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports...

02/21/2023

📢Avivagen Reports Fiscal Year 2022 Financial Results and Strategic Initiatives to Accelerate Growth
👉New approvals for sales in multiple countries
👉Raised more than $8.5 million in equity and debt financing
👉Revenues of approximately $1 million
👉Succession plan implemented to support next phase of accelerated growth

Read the full release here: https://avivagen.com/fiscal-2022-results/

01/19/2023

📙We're proud to announce publication of a new paper in the journal Animals.

The Publication showcases the cumulative understanding to-date of Avivagen’s product from both a scientific and real world application perspective.

🔍More details:

https://avivagen.com/scientific-commercial-evidence/

$VIV.V

Publication showcases the cumulative understanding to-date of Avivagen’s product from both a scientific and real world application perspective Product’s value and safety has been shown through use in many settings, under differing conditions and in millions of animals   Ottawa, ON /Business Wir...

11/01/2022

📈Avivagen Inc. Announces Closing of Second Tranche of a Private Placement of Shares

The Company issued 875,000 Common Shares, for aggregate gross proceeds of $175,000 in the Second Tranche. In the aggregate of all two tranches of the Offering, the Company issued 3,025,000 Common Shares for gross proceeds of $605,000.

Ottawa, ON / Business Wire/ October 31, 2022 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, ther...